Columbia Accelerator Network (CAN)
Entrepreneurial education and access to funding for validation and prototyping is critical to transitioning early-stage technologies out of the lab and bringing them to market at a faster rate.
Columbia has extensive experience founding and supporting successful accelerator programs to provide our promising early‐stage technologies with mentorship and support resources, direct funding, educational boot camps, networking opportunities with industry representatives and the venture investor community.
The Columbia Accelerator Network (CAN) currently encompasses four proof‐of‐concept programs across separate industries: medical technologies, clean technology & energy, digital media, and therapeutics. Many of these programs are explicitly multi-institutional and involve extensive collaboration with our peer universities and their tech transfer offices.
To learn more about the Columbia Accelerator Network please see below or contact firstname.lastname@example.org
The U.S. invests billions of dollars in healthcare research at institutions across the country with the goal of benefitting society. However, even the most promising technologies often fail to reach patients due to the high-risk path biomedical technologies face moving from the lab to the market. The Columbia Biomedical Accelerator (formally the Columbia-Coulter Translational Research Partnership) aims to catalyze the advancement of biomedical technologies by providing funding, education, resources and mentorship to interdisciplinary teams of clinicians, engineers, scientists and students working to develop solutions to clinical unmet needs, with the ultimate goal of bringing innovative research out of the lab to benefit society. Project support is expected to serve as a bridge to commercial investment, with awards granted to perform specific tasks needed to validate a commercial hypothesis (vs. a scientific hypothesis). For more information, please visit: www.columbia-coulter.org
NYC Media Lab connects digital media and technology companies with New York City's universities to drive innovation, entrepreneurship, talent development and job growth. A public-private partnership launched by the New York City Economic Development Corporation, NYC Media Lab funds prototyping projects that foster collaboration across a range of disciplines core to the future of media, in addition to producing The Combine, an early stage accelerator for emerging media and technology startups. NYC Media Lab is built on corporate membership. Member companies participate in roundtable events on technology issues; connect with one another and with faculty, students, and other university resources; and direct prototyping projects on areas of interest to them. For more information, please visit: http://nycmedialab.org
PowerBridgeNY turns cleantech innovations from the academic research labs at six New York institutions (Columbia, NYU, CUNY, CornellTech, Stony Brook University, and Brookhaven National Lab) into strong, cleantech businesses. Teams are offered up to $150K to conduct 100 Customer Discovery interviews to identify their initial target market and to develop a prototype or conduct in-field testing to move the technology closer to commercialization. PowerBridgeNY conducts monthly check-ins using the NSF I-Corps/Lean LaunchPad Methodology; provides industry mentors; hosts events featuring the energy industry; subsidizes the cost of necessary services; and arranges pro bono office hours with experts in law, finance, grant writing, and more. The program is funded by the New York State Energy Research and Development Authority (NYSERDA). For more information, please visit: http://powerbridgeny.com/
The Translational Therapeutics (Trx) Resource is an accelerator program designed to leverage Columbia’s proficiency in drug discovery and provide access to industry experts with the goal of advancing novel therapeutics from the lab towards the path of commercialization. The TRx Resource provides education (5-session boot camp), mentorship (drug development team) and funding (Pilot Award) to help translational researchers reach a point of value inflection. While indication agnostic, the educational aspect of the program provides a special focus on orphan/rare diseases. For more information, please visit: TRx Resource